Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study

Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL 3rd, et al.

Prostate 2016 Feb;76(3):286-93.

Abstract
 

BACKGROUND:

Fyn is a kinase that is upregulated in a subset of metastatic castration-resistant prostate cancer. Saracatinib potently inhibits Fyn activation. We have noted a relationship between Fyn expression and directional motility, a cellular process related to metastasis. As such we hypothesized that treatment with saracatinib would increase the time required to develop new metastatic lesions.

METHODS:

Patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel were eligible for enrollment. This study was executed as a randomized discontinuation trial. During a lead-in phase of two 28-Day cycles, all patients received saracatinib. Afterward, patients with radiographically stable disease were randomized to either saracatinib or placebo. Patients continued treatment until evidence of new metastasis.

RESULTS:

Thirty-one patients were treated. Only 26% of patients had stable disease after 8 weeks and thus proceeded to randomization. This required early termination of the study for futility. The 70% of patients who progressed after the lead-in phase exhibited expansion of existing lesions or decompensation due to clinical progression without new metastatic lesions. Fatigue was reported in more than 25% of patients (all grades) with only two patients experiencing grade 3 toxicity. Other grade 3 adverse events included dehydration, thrombocytopenia, and weakness.

CONCLUSIONS:

This study was unable to determine if saracatinib had potential as metastasis inhibitor. Metastasis inhibition by saracatinib may still be viable in an earlier time in the disease history. Prostate 76:286-293, 2016. © 2015 Wiley Periodicals, Inc.

©PubMed Central

Share

E-Alert

Register to be notified when new content is published. Only your name, country and email address needed.

Subscribe »

EAU 2016 Scientific Programme and Sessions

View the Scientific Programme and Sessions of the 2016 EAU Annual Congress, Munich, Germany.

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.
The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views

Search this site

Search form